FDA Grants Nivolumab Priority Review in Head and Neck Cancer

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in metastatic head and neck cancer.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in recurrent or metastatic head and neck cancer, based on results of the CheckMate-141 study.

The study found that nivolumab improved overall survival (7.5 vs 5.1 months) over investigator’s choice.

Recent Videos
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Overall survival also appears to improve with toripalimab compared with chemotherapy among patients with metastatic or advanced nasopharyngeal carcinoma.
head and neck cancer
head and neck cancer
head and neck cancer
Related Content
Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC

Durvalumab Is Not Statistically Significant Vs Cetuximab in HNSCC

Ariana Pelosci
March 13th 2025
Article

The trial was terminated early due to no statistical significance observed between durvalumab and cetuximab for patients with head and neck squamous cell carcinoma.

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 15th 2017
Podcast

In this interview we discuss new clinical guidelines from ASTRO on the use of radiotherapy in treating oropharyngeal cancer.

Support for the supplemental biologics license application is based on phase 3 KEYNOTE-689 trial data.

Pembrolizumab Earns FDA Priority Review in Locally Advanced HNSCC

Roman Fabbricatore
February 25th 2025
Article

Support for the supplemental biologics license application is based on phase 3 KEYNOTE-689 trial data.

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Petosemtamab Combo Earns Breakthrough Therapy Status in PD-L1+ HNSCC

Russ Conroy
February 20th 2025
Article

Investigators will assess treatment with petosemtamab among patients with PD-L1–positive HNSCC in the phase 3 LiGeR-HN1 and LiGeR-HN2 trials.

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN

Russ Conroy
February 1st 2025
Article

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Nivolumab/Cisplatin/Radiotherapy Improves DFS in Locally Advanced SCCHN

Tim Cortese
January 9th 2025
Article

The phase 3 NIVOPOSTOP GORTEC 2018-01 trial shows that nivolumab added to radiotherapy and cisplatin had improved efficacy over SOC treatments in SCCHN.